Gen Digital Secures Major Legal Victory After Overturning $481 Million Patent Award in Columbia University Dispute

Gen Digital has achieved a decisive legal win after a federal appellate court vacated a $481 million verdict in favor of Columbia University, reversing a 2024 judgment that had found the company liable for infringing on a university-developed digital security patent. The ruling, issued on March 11, 2026, stems from a complex dispute over a patent related to user authentication and data encryption technologies used in Gen Digital’s cybersecurity platforms, including its Norton and Avast brands. The original jury award, which had raised concerns about the enforceability of academic patents in commercial software, triggered widespread scrutiny across the technology sector. The appellate court determined that the lower court had erred in its claim construction and allowed expert testimony that improperly favored the university’s interpretation of the patent claims. This procedural misstep, the court concluded, undermined the fairness of the verdict and warranted a full reversal. The overturning of the judgment eliminates an immediate financial liability for Gen Digital, which had previously provisioned for the potential payout and faced investor concerns about long-term litigation risk. The company’s stock, trading under the ticker GEN, saw a 7.3% increase in after-hours trading following the announcement, while the broader S&P 500 Tech Sector Index remained flat. The S&P 500 and CBOE Volatility Index (VIX) also saw modest movements, with CL=F (West Texas Intermediate crude) unaffected due to the case’s non-energy focus. This outcome may embolden other technology firms facing similar academic patent claims, particularly those involving foundational digital security or AI-driven infrastructure. The ruling reinforces the importance of rigorous claim construction and expert validation in IP litigation, potentially reshaping legal defenses in future disputes. Columbia University has not yet announced its plans for appeal, but the decision is expected to have lasting implications for how universities pursue commercial enforcement of federally funded research patents.